IntegrateRNA offers design and optimization services for ligand conjugates, to improve the cell/tissue-selective targeting and pharmacokinetic properties of your oligonucleotide drugs. Based on extensive experience in the oligonucleotide bioconjugation field, we help customers find effective ligand conjugates, including but not limited to lipophilic molecules, carbohydrates, antibodies, proteins, aptamers, peptides, and polymers.
Oligonucleotide therapies possess enormous potential as healing, life-changing, and cancer-curing drugs. Bioconjugates offer the potential to deliver the oligonucleotide to a specific cell or tissue and thus minimize drug exposure to other parts of the body and improve the safety of the drug. Conjugation of oligonucleotides to targeting ligands can also improve the pharmacokinetic properties of oligonucleotides (short therapeutic RNA or DNA molecules) and expand their scope of application. Many biomolecules like GalNAc, CPP, CD71 antibody, PEG and cholesterol, have been investigated and applied in pre-clinical and clinical practices.
